52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Morphosys Says Licensing Partner GSK Shared Prelim Results From OSCAR Study With Otilimab
EMA Says CHMP Endorses GSK's Dostarlimab For Treatment Of Advanced Endometrial Cancer
Dodge & Cox Discloses 5.04% Stake In GSK As Of Feb. 19 - Filing
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
G S K House, 980 Great West Road
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
GlaxoSmithKline will extend a trial testing an experimental rheumatoid arthritis drug on patients suffering from pneumonia related to COVID-19 to focus on the elderly as it seeks to firm up encouraging findings so far.
* DODGE & COX DISCLOSES 5.04% STAKE IN GSK AS OF FEB. 19 - FILING Source text for Eikon: Further company coverage:
A Federal Circuit U.S. Court of Appeals panel agreed Tuesday hear new arguments on its October decision that Teva Pharmaceutical Industries Ltd's generic version of GlaxoSmithKline PLC's heart drug Coreg infringed a GSK patent, even though Teva's drug came with a so-called...
GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot's launch.
* GLAXOSMITHKLINE PLC - SANOFI AND GSK INITIATE NEW PHASE 2 STUDY
* GSK - THE COMPANY WILL NOW EXTEND TARGET TO INCREASE FEMALE REPRESENTATION IN VP LEVEL AND ABOVE ROLES TO AT LEAST 45% BY 2025
* GSK, ON SANDOZ DEAL, SAYS PROPOSES TO CLOSE ITS CEPHALOSPORINS MANUFACTURING OPERATIONS ONCE TRANSFER OF MANUFACTURING OPERATIONS TO SANDOZ IS COMPLETE
Swiss drugmaker Novartis' generics division is buying a GlaxoSmithKline antibiotics business that includes the brands Zinnat, Zinacef and Fortum for up to $500 million, the drugmakers said on Thursday.
The full Federal Circuit U.S. Court of Appeals agreed Tuesday to a review of an October panel decision that Teva Pharmaceutical Industries Ltd's generic version of GlaxoSmithKline PLC's heart drug Coreg infringed a GSK patent, even though Teva's drug came with a so-called...
Britain's GlaxoSmithKline and German biotech firm CureVac have teamed up in a 150 million euro ($180 million) deal to develop a COVID-19 vaccine from next year that could target several variants with one shot.
* CO, CUREVAC N.V. TODAY ANNOUNCED A NEW EUR 150M COLLABORATION
China's Clover Biopharmaceuticals said on Monday it has terminated its partnership with GlaxoSmithKline Plc (GSK) to develop a COVID-19 vaccine using the British drug maker's adjuvant.
Eli Lilly and Co is testing its COVID-19 antibody therapy in combination with another treatment by Vir Biotechnology Inc and its partner GlaxoSmithKline , in an effort to combat new variants of the coronavirus.
Eli Lilly and Co said on Wednesday it would test a combination of its COVID-19 antibody therapy with another treatment by Vir Biotechnology Inc and its partner GlaxoSmithKline.
* LILLY, VIR BIOTECHNOLOGY AND GSK ANNOUNCE FIRST PATIENT DOSED IN EXPANDED BLAZE-4 TRIAL EVALUATING BAMLANIVIMAB (LY-COV555) WITH VIR-7831 (GSK4182136) FOR COVID-19
French pharmaceutical giant Sanofi said on Wednesday it had struck an agreement with Germany's BioNTech to supply the European Union with the company's vaccine developed in partnership with U.S. group Pfizer.
The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare.
Merck KGaA's drug development programme has suffered a setback with its most important experimental drug, cancer treatment bintrafusp alfa, failing early in its lead trial.
Germany's Merck KGaA said the most important clinical trial testing its cancer drug hopeful bintrafusp alfa, which it is co-developing with GlaxoSmithKline, would be stopped because the treatment does not appear to work.
The U.S. Food and Drug Administration has rejected GlaxoSmithKline's request to weigh in on a key question in lawsuits by women who say the drugmaker failed to warn them that taking the anti-nausea drug Zofran during pregnancy can cause birth defects.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.